Does aspirin use reduce cardiovascular risk in diabetes?

Nat Rev Endocrinol. 2009 Apr;5(4):188-90. doi: 10.1038/nrendo.2009.44.

Abstract

The use of aspirin for the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus is controversial. According to the findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular events in this group of patients, unless they are aged 65 years and above.

Publication types

  • Comment

MeSH terms

  • Aspirin / administration & dosage
  • Aspirin / therapeutic use*
  • Atherosclerosis / complications*
  • Atherosclerosis / epidemiology
  • Atherosclerosis / etiology
  • Atherosclerosis / prevention & control*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use*

Substances

  • Platelet Aggregation Inhibitors
  • Aspirin